CHICAGO, July 2, 2024 /PRNewswire/ -- The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™ (donanemab, Eli Lilly) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques.
“This is real progress. Today’s approval allows people more options and greater opportunity to have more time,” said Joanne Pike, DrPH, Alzheimer’s Association president and CEO. “Having multiple treatment options is the kind of advancement we’ve all been waiting for — all of us who have been touched, even blindsided, by this difficult and devastating disease.”
Because multiple FDA-approved Alzheimer’s treatments are now available, early detection and diagnosis are even more critical to ensure individuals receive the most benefit. Access to these treatments should not be delayed at any stage or by any entity — not the Centers for Medicare & Medicaid Services (CMS) coverage with evidence development policy, private insurers, health systems or doctors.
“Too many roadblocks have prevented individuals from getting equitable access to these beneficial treatments for far too long,” said Pike. “It is equally important that clinicians and health care systems are informed and prepared to help the individuals who could benefit. The Alzheimer’s Association is working with health systems and providers to ensure they have the tools and resources to meet the needs of their patients.”
The Association strongly encourages prescribers to participate in the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), which is gathering real world data on how people from all backgrounds and communities respond to novel FDA-approved Alzheimer’s therapies. ALZ-NET provides ongoing education and resources for clinicians, patients, and families, helping them stay informed about the latest developments in Alzheimer’s research and care.
“These recent approvals generate hope for continued advances. For researchers, our next horizon is to develop new treatments that address different components of the disease, and that work together to have an even bigger effect on slowing or stopping disease progression for all communities,” said Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead, Alzheimer’s Association.
This is the third approval of an Alzheimer’s treatment that changes the underlying course of the disease. Results from studies of a wide variety of Alzheimer’s and dementia therapies will be reported at the Alzheimer’s Association International Conference® (AAIC®), July 28 to August 1 in Philadelphia.
“Today’s decision by the FDA is good news for those of us living with early Alzheimer’s,” said Barbara Eades, of Chattanooga, Tennessee, who was diagnosed with mild cognitive impairment (MCI) in 2018. “I was fortunate to participate in the clinical trial and receive this treatment. It has provided me an opportunity to live my life fully, for more time. I’m able to keep doing what I’m passionate about: sing, remain active in my church and spend time with my friends and family.”
The Alzheimer’s Association is disappointed that so little progress is being made to improve representation of all affected populations in Alzheimer’s clinical trials. For example, Alzheimer’s and other dementia disproportionately affect Black/African Americans and Hispanic/Latino Americans yet, too often, these groups are severely underrepresented in treatment studies. It is critical that clinical trial study populations reflect the communities these treatments intend to serve.
If you or a loved one is experiencing memory changes, the Alzheimer’s Association strongly encourages speaking with a health care provider for a thorough evaluation and diagnosis and to discuss treatment options. For more information on diagnosis or to find a local health care provider, visit the Alzheimer’s Association at alz.org, or the Helpline 24/7 at 800.272.3900.
Alzheimer’s Association
The Alzheimer’s Association leads the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia. Visit alz.org or call the 24/7 Helpline at 800.272.3900.
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-association-welcomes-us-fda-approval-of-kisunla-donanemab-302188365.html
SOURCE Alzheimer’s Association
